Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H25F3N2OS |
| Molecular Weight | 434.518 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC4=CC=C(C=C24)C(F)(F)F)CC1
InChI
InChIKey=NJMYODHXAKYRHW-DVZOWYKESA-N
InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-
Flupenthixol is a thioxanthene antipsychotic used in the treatment of schizophrenia and other psychoses, with the exception of mania and psychomotor hyperactivity due to an activating effect associated with this drug. It may also be employed as an antidepressant. Flupenthixol has a wide range of pharmacological actions. Flupenthixol blocks dopaminergic receptors, thus interfering with dopaminergic transmission in the brain. Flupenthixol also inhibits serotonin 5-HT, histamine H1, muscarinic and alpha-1 adrenergic receptors.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A controlled comparison of flupenthixol and amitriptyline in depressed outpatients. | 1976 May 8 |
|
| Strain differences in clonidine-induced aggressiveness in mice and its interaction with the dopamine system. | 1993 Apr |
|
| Depot flupenthixol-induced mania. | 1993 Jun |
|
| Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. | 1994 Feb 1 |
|
| Expression and pharmacological characterization of the human D3 dopamine receptor. | 1994 Jan |
|
| Convulsions after enflurane in a schizophrenic patient receiving neuroleptics. | 1994 May |
|
| High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. | 1994 Nov 11 |
|
| Mitochondrial involvement in schizophrenia and other functional psychoses. | 1996 Sep |
|
| Tolerability of low dose neuroleptics: a case control study of flupenthixol. | 1997 Nov |
|
| Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study. | 1998 Aug |
|
| [Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006 Jun |
Patents
Sample Use Guides
Fluanxol® (flupentixol) 0.5 mg and 1 mg film-coated tablets. The starting dose is usually 1 mg daily taken as a single dose in the morning. This may be increased to 2 mg per day after one week. The maximum daily dose is 3 mg per day. Fluanxol® (flupenthixol decanoate) Depot 20 mg/mL, Concentrated Depot 100 mg/mL. Generally, the starting dose is 20 to 40 mg (1 to 2 mL). A second dose of 20 to 40 mg (1 to 2 mL) is usually given 4-10 days after the first injection, and further doses are given every 2 to 4 weeks for the majority of patients.
Route of Administration:
oral, intramuscular
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
53772-82-0
Created by
admin on Tue Mar 06 11:44:57 UTC 2018 , Edited by admin on Tue Mar 06 11:44:57 UTC 2018
|
PRIMARY | |||
|
258-756-4
Created by
admin on Tue Mar 06 11:44:57 UTC 2018 , Edited by admin on Tue Mar 06 11:44:57 UTC 2018
|
PRIMARY | |||
|
5281881
Created by
admin on Tue Mar 06 11:44:57 UTC 2018 , Edited by admin on Tue Mar 06 11:44:57 UTC 2018
|
PRIMARY | SWITZERF | ||
|
53772-82-0
Created by
admin on Tue Mar 06 11:44:57 UTC 2018 , Edited by admin on Tue Mar 06 11:44:57 UTC 2018
|
PRIMARY |
SUBSTANCE RECORD
